• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …

Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium
not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a …

Myocardial diseases are associated with an increased risk of potentially fatal cardiac
arrhythmias and sudden cardiac death/cardiac arrest during exercise, including hypertrophic …

This paper is dedicated to the memory of our friends recently passed away, Drs Guy
Fontaine, Andrea Nava, and Nikos Protonotarios, who played a pioneering role in the …

In the absence of contemporary, population-based epidemiological studies, estimates of the
incidence and prevalence of the inherited cardiomyopathies have been derived from …

In the past 25 years, major advances were achieved in the nosography of cardiomyopathies,
influencing the definition and taxonomy of this important chapter of cardiovascular disease …

The J-wave syndromes (JWSs), consisting of the Brugada syndrome (BrS) and early
repolarization syndrome (ERS), have captured the interest of the cardiology community over …

Background: Cardiomyopathies are a heterogeneous group of pathologies characterized by
structural and functional alterations of the heart. Aims: The purpose of this narrative review is …